{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:05:45Z","timestamp":1792191945903,"version":"4.4.0"},"publisher-location":"Cham","reference-count":165,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031667756","type":"print"},{"value":"9783031667763","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/164_2023_678","type":"book-chapter","created":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T19:02:12Z","timestamp":1689534132000},"page":"333-367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Adrenoceptors in the Lower Urinary Tract"],"prefix":"10.1007","author":[{"given":"Martin","family":"Hennenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"issue":"1","key":"678_CR1","first-page":"81","volume":"291","author":"K Akiyama","year":"1999","unstructured":"Akiyama K et al (1999) KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther 291(1):81\u201391","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"678_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1046\/j.1442-2042.2001.00277.x","volume":"8","author":"K Akiyama","year":"2001","unstructured":"Akiyama K et al (2001) Effect of KMD-3213, an alpha1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs. Int J Urol 8(4):177\u2013183","journal-title":"Int J Urol"},{"issue":"3","key":"678_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/bph.13367","volume":"173","author":"EC Alexandre","year":"2016","unstructured":"Alexandre EC et al (2016) Mirabegron relaxes urethral smooth muscle by a dual mechanism involving beta3 -adrenoceptor activation and alpha1 -adrenoceptor blockade. Br J Pharmacol 173(3):415\u2013428","journal-title":"Br J Pharmacol"},{"key":"678_CR4","first-page":"577","volume-title":"Handbook of experimental pharmacology","author":"K-E Andersson","year":"2011","unstructured":"Andersson K-E, Michel MC (2011) Urinary tract. In: Hofmann FB (ed) Handbook of experimental pharmacology, vol 202. Springer Verlag, Heidelberg, p 577"},{"issue":"3","key":"678_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00345-014-1336-z","volume":"33","author":"E Aro","year":"2015","unstructured":"Aro E et al (2015) Is there a peripheral site of action contributing to the voiding effects of alpha(2)-adrenoceptor agonists and antagonists? World J Urol 33(3):433\u2013440","journal-title":"World J Urol"},{"issue":"4","key":"678_CR6","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/j.1476-5381.1989.tb11913.x","volume":"96","author":"H Azuma","year":"1989","unstructured":"Azuma H et al (1989) Alpha 1-adrenoceptor antagonist activity of novel pyrimidine derivatives (SHI437 and IK29) in rabbit aorta and trigone of the bladder. Br J Pharmacol 96(4):1000\u20131006","journal-title":"Br J Pharmacol"},{"issue":"Suppl 4","key":"678_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1464-410X.2005.05487.x","volume":"95","author":"MM Barendrecht","year":"2005","unstructured":"Barendrecht MM et al (2005) Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int 95(Suppl 4):19\u201328","journal-title":"BJU Int"},{"issue":"3","key":"678_CR8","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/nau.20481","volume":"27","author":"MM Barendrecht","year":"2008","unstructured":"Barendrecht MM et al (2008) Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn 27(3):226\u2013230","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"678_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/nau.20642","volume":"28","author":"MM Barendrecht","year":"2009","unstructured":"Barendrecht MM et al (2009) The effect of bladder outlet obstruction on \u03b11- and \u00df-adrenoceptor expression and function. Neurourol Urodyn 28(4):349\u2013355","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"678_CR10","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S0022-5347(17)58733-9","volume":"116","author":"GS Benson","year":"1976","unstructured":"Benson GS et al (1976) Adrenergic and cholinergic stimulation and blockade of the human bladder base. J Urol 116(2):174\u2013175","journal-title":"J Urol"},{"issue":"6","key":"678_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1177\/1060028014524174","volume":"48","author":"K Boyd","year":"2014","unstructured":"Boyd K, Hilas O (2014) alpha-adrenergic blockers for the treatment of lower-urinary-tract symptoms and dysfunction in women. Ann Pharmacother 48(6):711\u2013722","journal-title":"Ann Pharmacother"},{"issue":"5","key":"678_CR12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0090-4295(01)01344-9","volume":"58","author":"P Boyle","year":"2001","unstructured":"Boyle P et al (2001) Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 58(5):717\u2013722","journal-title":"Urology"},{"issue":"4","key":"678_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/sj.bjp.0705840","volume":"142","author":"N Brahmadevara","year":"2004","unstructured":"Brahmadevara N, Shaw AM, MacDonald A (2004) ALpha1-adrenoceptor antagonist properties of CGP 12177A and other beta-adrenoceptor ligands: evidence against beta(3)- or atypical beta-adrenoceptors in rat aorta. Br J Pharmacol 142(4):781\u2013787","journal-title":"Br J Pharmacol"},{"key":"678_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejphar.2014.09.030","volume":"744","author":"R Buono","year":"2014","unstructured":"Buono R et al (2014) Silodosin and tadalafil have synergistic inhibitory effects on nerve-mediated contractions of human and rat isolated prostates. Eur J Pharmacol 744:42\u201351","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"678_CR15","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/pros.22930","volume":"75","author":"FB Calmasini","year":"2015","unstructured":"Calmasini FB et al (2015) The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication? Prostate 75(4):440\u2013447","journal-title":"Prostate"},{"issue":"6","key":"678_CR16","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/bju.14454","volume":"122","author":"T Campschroer","year":"2018","unstructured":"Campschroer T et al (2018) \u03b1-blockers as medical expulsive therapy for ureteric stones: a Cochrane systematic review. BJU Int 122(6):932\u2013945","journal-title":"BJU Int"},{"key":"678_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000100830","volume":"78","author":"AE Canda","year":"2007","unstructured":"Canda AE et al (2007) Physiology and pharmacology of the human ureter: basis for current and future treatments. Urol Int 78:289\u2013298","journal-title":"Urol Int"},{"issue":"5","key":"678_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1124\/mol.114.092817","volume":"86","author":"H Cernecka","year":"2014","unstructured":"Cernecka H, Sand C, Michel MC (2014) The odd sibling: features of \u00df3-adrenoceptor pharmacology. Mol Pharmacol 86(5):479\u2013484","journal-title":"Mol Pharmacol"},{"key":"678_CR19","first-page":"1","volume":"202","author":"C Chapple","year":"2011","unstructured":"Chapple C (2011) Overview on the lower urinary tract. Handb Exp Pharmacol 202:1\u201314","journal-title":"Handb Exp Pharmacol"},{"issue":"3","key":"678_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.eururo.2010.10.046","volume":"59","author":"CR Chapple","year":"2011","unstructured":"Chapple CR et al (2011) Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 59(3):342\u2013352","journal-title":"Eur Urol"},{"issue":"1","key":"678_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/nau.22505","volume":"33","author":"CR Chapple","year":"2014","unstructured":"Chapple CR et al (2014) Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn 33(1):17\u201330","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"678_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000241674","volume":"83","author":"E Costantini","year":"2009","unstructured":"Costantini E et al (2009) Open-label, longitudinal study of tamsulosin for functional bladder outlet obstruction in women. Urol Int 83(3):311\u2013315","journal-title":"Urol Int"},{"key":"678_CR23","doi-asserted-by":"publisher","first-page":"651635","DOI":"10.3389\/fneur.2021.651635","volume":"12","author":"Y Cui","year":"2021","unstructured":"Cui Y et al (2021) Trigonal-sparing vs. trigonal-involved onabotulinumtoxinA injection for the treatment of overactive bladder: a systematic review and meta-analysis. Front Neurol 12:651635","journal-title":"Front Neurol"},{"key":"678_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.coph.2014.03.003","volume":"16C","author":"PR Dale","year":"2014","unstructured":"Dale PR et al (2014) The pharmacological rationale for combining muscarinic receptor antagonists and \u00df-adrenoceptor agonists in the treatment of airway and bladder disease. Curr Opin Pharmacol 16C:31\u201342","journal-title":"Curr Opin Pharmacol"},{"issue":"7","key":"678_CR25","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1016\/j.bmc.2007.01.056","volume":"15","author":"C Dallanoce","year":"2007","unstructured":"Dallanoce C et al (2007) Novel chiral isoxazole derivatives: synthesis and pharmacological characterization at human beta-adrenergic receptor subtypes. Bioorg Med Chem 15(7):2533\u20132543","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"678_CR26","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S0022-5347(05)66049-1","volume":"166","author":"H Danuser","year":"2001","unstructured":"Danuser H et al (2001) Systemic and topical drug administration in the pig ureter: effect of phosphodiesterase inhibitors \u03b11, \u00df and \u00df2-adrenergic receptor agonists and antagonists on the frequency and amplitude of ureteral contractions. J Urol 166(2):714\u2013720","journal-title":"J Urol"},{"issue":"2","key":"678_CR27","first-page":"527","volume":"278","author":"V Deplanne","year":"1996","unstructured":"Deplanne V, Galzin AM (1996) Functional characterization of alpha-1-adrenoceptor subtypes in the prostatic urethra and trigone of male rabbit. J Pharmacol Exp Ther 278(2):527\u2013534","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"678_CR28","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.urology.2004.08.049","volume":"64","author":"B Djavan","year":"2004","unstructured":"Djavan B et al (2004) Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology 64(6):1144\u20131148","journal-title":"Urology"},{"issue":"1\u20132","key":"678_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000519720","volume":"107","author":"BR Erdogan","year":"2022","unstructured":"Erdogan BR et al (2022a) Validation of fenoterol to study \u03b22-adrenoceptor function in the rat urinary bladder. Pharmacology 107(1\u20132):116\u2013121","journal-title":"Pharmacology"},{"issue":"8","key":"678_CR30","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00210-022-02249-9","volume":"395","author":"BR Erdogan","year":"2022","unstructured":"Erdogan BR et al (2022b) Established and emerging treatments for diabetes-associated lower urinary tract dysfunction. Naunyn Schmiedeberg\u2019s Arch Pharmacol 395(8):887\u2013906","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"678_CR31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.urology.2017.05.011","volume":"106","author":"K Eredics","year":"2017","unstructured":"Eredics K, Madersbacher S, Schauer I (2017) A relevant midterm (12 months) placebo effect on lower urinary tract symptoms and maximum flow rate in male lower urinary tract symptom and benign prostatic hyperplasia \u2013 a meta-analysis. Urology 106:160\u2013166","journal-title":"Urology"},{"issue":"30","key":"678_CR32","doi-asserted-by":"publisher","first-page":"20329","DOI":"10.1016\/S0021-9258(18)54927-9","volume":"266","author":"B Feve","year":"1991","unstructured":"Feve B et al (1991) Atypical beta-adrenergic receptor in 3T3-F442A adipocytes. Pharmacological and molecular relationship with the human beta 3-adrenergic receptor. J Biol Chem 266(30):20329\u201320336","journal-title":"J Biol Chem"},{"issue":"4","key":"678_CR33","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/nau.20903","volume":"29","author":"CH Fry","year":"2010","unstructured":"Fry CH et al (2010a) Animal models and their use in understanding lower urinary tract dysfunction. Neurourol Urodyn 29(4):603\u2013608","journal-title":"Neurourol Urodyn"},{"issue":"1\u20132","key":"678_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.autneu.2009.10.006","volume":"154","author":"CH Fry","year":"2010","unstructured":"Fry CH, Meng E, Young JS (2010b) The physiological function of lower urinary tract smooth muscle. Auton Neurosci 154(1\u20132):3\u201313","journal-title":"Auton Neurosci"},{"issue":"3","key":"678_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/luts.12065","volume":"7","author":"A Furuta","year":"2015","unstructured":"Furuta A et al (2015) Noradrenergic mechanisms controlling urethral smooth and striated muscle function in urethral continence reflex in rats. Low Urin Tract Symptoms 7(3):155\u2013161","journal-title":"Low Urin Tract Symptoms"},{"issue":"6","key":"678_CR36","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.eururo.2015.12.034","volume":"69","author":"F Fusco","year":"2016","unstructured":"Fusco F et al (2016) a1-blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies. Eur Urol 69(6):1091\u20131101","journal-title":"Eur Urol"},{"issue":"6","key":"678_CR37","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1111\/jsm.12525","volume":"11","author":"M Gacci","year":"2014","unstructured":"Gacci M et al (2014) Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med 11(6):1554\u20131566","journal-title":"J Sex Med"},{"key":"678_CR38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/BF00941983","volume":"25","author":"M Goepel","year":"1997","unstructured":"Goepel M et al (1997) Comparison of adrenoceptor subtype expression in porcine and human bladder and prostate. Urol Res 25:199\u2013206","journal-title":"Urol Res"},{"issue":"1\u20133","key":"678_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejphar.2007.05.035","volume":"570","author":"JM Haynes","year":"2007","unstructured":"Haynes JM (2007) beta(2) and beta(3)-adrenoceptor inhibition of alpha(1)-adrenoceptor-stimulated Ca(2+) elevation in human cultured prostatic stromal cells. Eur J Pharmacol 570(1\u20133):18\u201326","journal-title":"Eur J Pharmacol"},{"key":"678_CR40","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/B978-0-12-820472-6.00079-7","volume-title":"Comprehensive pharmacology","author":"M Hennenberg","year":"2022","unstructured":"Hennenberg M (2022) Pharmacology of the prostate in non-infectious diseases. In: Kenakin T (ed) Comprehensive pharmacology, 1st edn. Elsevier, pp 708\u2013744","edition":"1"},{"issue":"2","key":"678_CR41","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00345-010-0634-3","volume":"29","author":"M Hennenberg","year":"2011","unstructured":"Hennenberg M et al (2011a) beta-arrestin-2 is expressed in human prostate smooth muscle and a binding partner of alpha1A-adrenoceptors. World J Urol 29(2):157\u2013163","journal-title":"World J Urol"},{"issue":"6","key":"678_CR42","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/j.1464-410X.2010.10021.x","volume":"108","author":"M Hennenberg","year":"2011","unstructured":"Hennenberg M et al (2011b) alpha1-adrenoceptor activation induces phosphorylation of beta2-adrenoceptors in human prostate tissue. BJU Int 108(6):922\u2013928","journal-title":"BJU Int"},{"issue":"10","key":"678_CR43","doi-asserted-by":"publisher","first-page":"F1383","DOI":"10.1152\/ajprenal.00380.2013","volume":"305","author":"M Hennenberg","year":"2013","unstructured":"Hennenberg M et al (2013a) The receptor antagonist picotamide inhibits adrenergic and thromboxane-induced contraction of hyperplastic human prostate smooth muscle. Am J Physiol Renal Physiol 305(10):F1383\u2013F1390","journal-title":"Am J Physiol Renal Physiol"},{"issue":"7","key":"678_CR44","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/pros.22614","volume":"73","author":"M Hennenberg","year":"2013","unstructured":"Hennenberg M et al (2013b) Noradrenaline induces binding of clathrin light chain A to alpha1-adrenoceptors in the human prostate. Prostate 73(7):715\u2013723","journal-title":"Prostate"},{"issue":"7","key":"678_CR45","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/nau.22467","volume":"33","author":"M Hennenberg","year":"2014","unstructured":"Hennenberg M, Stief CG, Gratzke C (2014) Prostatic alpha1-adrenoceptors: new concepts of function, regulation, and intracellular signaling. Neurourol Urodyn 33(7):1074\u20131085","journal-title":"Neurourol Urodyn"},{"issue":"15","key":"678_CR46","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1002\/pros.23208","volume":"76","author":"M Hennenberg","year":"2016","unstructured":"Hennenberg M et al (2016) Inhibition of adrenergic and non-adrenergic smooth muscle contraction in the human prostate by the phosphodiesterase 10-selective inhibitor TC-E 5005. Prostate 76(15):1364\u20131374","journal-title":"Prostate"},{"key":"678_CR47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejphar.2017.03.022","volume":"803","author":"M Hennenberg","year":"2017","unstructured":"Hennenberg M et al (2017a) Inhibition of agonist-induced smooth muscle contraction by picotamide in the male human lower urinary tract outflow region. Eur J Pharmacol 803:39\u201347","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"678_CR48","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/pros.23293","volume":"77","author":"M Hennenberg","year":"2017","unstructured":"Hennenberg M et al (2017b) Non-adrenergic, tamsulosin-insensitive smooth muscle contraction is sufficient to replace alpha1 -adrenergic tension in the human prostate. Prostate 77(7):697\u2013707","journal-title":"Prostate"},{"issue":"1","key":"678_CR49","doi-asserted-by":"publisher","first-page":"F47","DOI":"10.1152\/ajprenal.00125.2017","volume":"314","author":"A Herlemann","year":"2018","unstructured":"Herlemann A et al (2018) Inhibition of smooth muscle contraction and ARF6 activity by the inhibitor for cytohesin GEFs, secinH3, in the human prostate. Am J Physiol Renal Physiol 314(1):F47\u2013F57","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"678_CR50","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/bju.13882","volume":"120","author":"S Herschorn","year":"2017","unstructured":"Herschorn S et al (2017) Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int 120(4):562\u2013575","journal-title":"BJU Int"},{"issue":"5","key":"678_CR51","first-page":"428","volume":"20","author":"J Hoffstedt","year":"1996","unstructured":"Hoffstedt J et al (1996) Effects of several putative beta 3-adrenoceptor agonists on lipolysis in human omental adipocytes. Int J Obes Relat Metab Disord 20(5):428\u2013434","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"2","key":"678_CR52","first-page":"512","volume":"239","author":"K Honda","year":"1986","unstructured":"Honda K, Nakagawa C (1986) Alpha-1 adrenoceptor antagonist effects of the optical isomers of YM-12617 in rabbit lower urinary tract and prostate. J Pharmacol Exp Ther 239(2):512\u2013516","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"678_CR53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/BF00586704","volume":"330","author":"K Honda","year":"1985","unstructured":"Honda K, Miyata-Osawa A, Takenaka T (1985) alpha 1-adrenoceptor subtype mediating contraction of the smooth muscle in the lower urinary tract and prostate of rabbits. Naunyn Schmiedeberg\u2019s Arch Pharmacol 330(1):16\u201321","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"678_CR54","doi-asserted-by":"publisher","first-page":"666047","DOI":"10.3389\/fphar.2021.666047","volume":"12","author":"R Huang","year":"2021","unstructured":"Huang R et al (2021) Concentration-dependent alpha1-adrenoceptor antagonism and inhibition of neurogenic smooth muscle contraction by mirabegron in the human prostate. Front Pharmacol 12:666047","journal-title":"Front Pharmacol"},{"issue":"1","key":"678_CR55","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/pros.24248","volume":"82","author":"R Huang","year":"2022","unstructured":"Huang R et al (2022) Inhibition of human prostate smooth muscle contraction by the inhibitors of protein kinase C, GF109203X, and Go6983. Prostate 82(1):59\u201377","journal-title":"Prostate"},{"issue":"14","key":"678_CR56","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1111\/bph.14658","volume":"176","author":"Y Igawa","year":"2019","unstructured":"Igawa Y, Aizawa N, Michel MC (2019) \u03b23-adrenoceptors in the normal and diseased urinary bladder \u2013 what are the open questions? Br J Pharmacol 176(14):2525\u20132538","journal-title":"Br J Pharmacol"},{"issue":"1","key":"678_CR57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0014-2999(01)01414-5","volume":"431","author":"PJ Kalodimos","year":"2001","unstructured":"Kalodimos PJ, Ventura S (2001) Beta2-adrenoceptor-mediated inhibition of field stimulation induced contractile responses of the smooth muscle of the rat prostate gland. Eur J Pharmacol 431(1):81\u201389","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"678_CR58","doi-asserted-by":"publisher","first-page":"744 e1\u20137","DOI":"10.1016\/j.urology.2011.08.080","volume":"79","author":"S Kanie","year":"2012","unstructured":"Kanie S et al (2012) Pharmacological effect of TRK-380, a novel selective human beta3-adrenoceptor agonist, on mammalian detrusor strips. Urology 79(3):744 e1\u20137","journal-title":"Urology"},{"issue":"6","key":"678_CR59","doi-asserted-by":"publisher","first-page":"1451 e13\u20139","DOI":"10.1016\/j.urology.2013.08.023","volume":"82","author":"GT Kedia","year":"2013","unstructured":"Kedia GT et al (2013) Pharmacologic characterization of human male urethral smooth muscle: an in vitro approach. Urology 82(6):1451 e13\u20139","journal-title":"Urology"},{"issue":"9","key":"678_CR60","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/pros.22647","volume":"73","author":"T Kitazawa","year":"2013","unstructured":"Kitazawa T (2013) Contractile signaling pathways in mouse prostate smooth muscle. Prostate 73(9):996\u20131006","journal-title":"Prostate"},{"key":"678_CR61","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00345-009-0396-y","volume":"27","author":"S Kobayashi","year":"2009","unstructured":"Kobayashi S et al (2009) Gene expression and mechanical functions of \u03b11-adrenoceptor subtypes in mouse ureter. World J Urol 27:775\u2013780","journal-title":"World J Urol"},{"issue":"10","key":"678_CR62","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/j.clinthera.2012.09.010","volume":"34","author":"W Krauwinkel","year":"2012","unstructured":"Krauwinkel W et al (2012) Pharmacokinetic properties of mirabegron, a beta3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther 34(10):2144\u20132160","journal-title":"Clin Ther"},{"issue":"1","key":"678_CR63","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/nau.24183","volume":"39","author":"MT Kummeling","year":"2020","unstructured":"Kummeling MT et al (2020) Initial report on distribution of beta3-adrenoceptor in the human female urethra. Neurourol Urodyn 39(1):125\u2013132","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"678_CR64","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/nau.22278","volume":"32","author":"Y Kurizaki","year":"2013","unstructured":"Kurizaki Y et al (2013) Relationship between expression of \u00df3-adrenoceptor mRNA in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Neurourol Urodyn 32(1):88\u201391","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"678_CR65","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4111\/icu.2020.61.4.419","volume":"61","author":"SY Kwon","year":"2020","unstructured":"Kwon SY et al (2020) Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: a prospective study. Investig Clin Urol 61(4):419\u2013424","journal-title":"Investig Clin Urol"},{"issue":"6","key":"678_CR66","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00210-009-0462-4","volume":"380","author":"N Kyprianou","year":"2009","unstructured":"Kyprianou N, Vaughan TB, Michel MC (2009) Apoptosis induction by doxazosin and other quinazoline \u03b11-adrenoceptor antagonists: a new mechanism for cancer treatment? Naunyn Schmiedeberg\u2019s Arch Pharmacol 380(6):473\u2013477","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"4","key":"678_CR67","first-page":"421","volume":"43","author":"A Labadia","year":"1987","unstructured":"Labadia A et al (1987) Alpha- and beta-adrenergic receptors in the horse ureter. Rev Esp Fisiol 43(4):421\u2013425","journal-title":"Rev Esp Fisiol"},{"issue":"1","key":"678_CR68","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1124\/jpet.103.061192","volume":"309","author":"V Leblais","year":"2004","unstructured":"Leblais V et al (2004) Role of alpha-adrenergic receptors in the effect of the beta-adrenergic receptor ligands, CGP 12177, bupranolol, and SR 59230A, on the contraction of rat intrapulmonary artery. J Pharmacol Exp Ther 309(1):137\u2013145","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"678_CR69","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/j.1476-5381.1993.tb13762.x","volume":"109","author":"F Lefevre-Borg","year":"1993","unstructured":"Lefevre-Borg F et al (1993) Alfuzosin, a selective alpha 1-adrenoceptor antagonist in the lower urinary tract. Br J Pharmacol 109(4):1282\u20131289","journal-title":"Br J Pharmacol"},{"issue":"Suppl 9","key":"678_CR70","first-page":"S3","volume":"6","author":"H Lepor","year":"2004","unstructured":"Lepor H (2004) Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol 6(Suppl 9):S3\u2013S10","journal-title":"Rev Urol"},{"issue":"1","key":"678_CR71","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/MOU.0b013e32834d9bfd","volume":"22","author":"H Lepor","year":"2012","unstructured":"Lepor H, Kazzazi A, Djavan B (2012) alpha-blockers for benign prostatic hyperplasia: the new era. Curr Opin Urol 22(1):7\u201315","journal-title":"Curr Opin Urol"},{"issue":"11","key":"678_CR72","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/pros.23998","volume":"80","author":"B Li","year":"2020","unstructured":"Li B et al (2020a) Inhibition of neurogenic and thromboxane A2 -induced human prostate smooth muscle contraction by the integrin alpha2beta1 inhibitor BTT-3033 and the integrin-linked kinase inhibitor Cpd22. Prostate 80(11):831\u2013849","journal-title":"Prostate"},{"issue":"17","key":"678_CR73","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1111\/bph.15172","volume":"177","author":"B Li","year":"2020","unstructured":"Li B et al (2020b) Regulation of smooth muscle contraction by monomeric non-RhoA GTPases. Br J Pharmacol 177(17):3865\u20133877","journal-title":"Br J Pharmacol"},{"key":"678_CR74","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.urology.2018.03.038","volume":"117","author":"CH Liao","year":"2018","unstructured":"Liao CH, Kuo HC (2018) Mirabegron 25\u2009mg monotherapy is safe but less effective in male patients with overactive bladder and bladder outlet obstruction. Urology 117:115\u2013119","journal-title":"Urology"},{"issue":"3","key":"678_CR75","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/JU.0000000000000309","volume":"202","author":"DJ Lightner","year":"2019","unstructured":"Lightner DJ et al (2019) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU Guideline Amendment 2019. J Urol 202(3):558\u2013563","journal-title":"J Urol"},{"issue":"7","key":"678_CR76","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00210-022-02244-0","volume":"395","author":"I Lim","year":"2022","unstructured":"Lim I, Chess-Williams R (2022) Mirabegron attenuates porcine ureteral contractility via \u03b11-adrenoceptor antagonism. Naunyn Schmiedeberg\u2019s Arch Pharmacol 395(7):839\u2013847","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"3","key":"678_CR77","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2478\/pjvs-2014-0078","volume":"17","author":"W Markiewicz","year":"2014","unstructured":"Markiewicz W et al (2014) The influence of doxazosin, an alpha1-adrenergic receptor antagonist on the urinary bladder contractility in pigs. Pol J Vet Sci 17(3):527\u2013529","journal-title":"Pol J Vet Sci"},{"issue":"3","key":"678_CR78","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1515\/pjvs-2017-0058","volume":"20","author":"W Markiewicz","year":"2017","unstructured":"Markiewicz W et al (2017) The influence of doxazosin on the contractility of the urinary bladder in female pigs with experimentally induced cystitis. Pol J Vet Sci 20(3):485\u2013490","journal-title":"Pol J Vet Sci"},{"issue":"2","key":"678_CR79","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.juro.2007.03.099","volume":"178","author":"D Mastrangelo","year":"2007","unstructured":"Mastrangelo D, Iselin CE (2007) Urothelium dependent inhibition of rat ureter contractile activity. J Urol 178(2):702\u2013709","journal-title":"J Urol"},{"issue":"10","key":"678_CR80","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/iju.12093","volume":"20","author":"R Matsumoto","year":"2013","unstructured":"Matsumoto R et al (2013) Expression and functional role of \u00df3-adrenoceptors in the human ureter. Int J Urol 20(10):1007\u20131014","journal-title":"Int J Urol"},{"issue":"25","key":"678_CR81","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell JD et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387\u20132398","journal-title":"N Engl J Med"},{"issue":"5","key":"678_CR82","first-page":"1054","volume":"224","author":"DG McLeod","year":"1973","unstructured":"McLeod DG, Reynolds DG, Swan KG (1973) Adrenergic mechanisms in the canine ureter. Am J Phys 224(5):1054\u20131058","journal-title":"Am J Phys"},{"issue":"5","key":"678_CR83","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0006-2952(99)00376-7","volume":"59","author":"RC Mehta","year":"2000","unstructured":"Mehta RC et al (2000) Biochemical and functional characterization of 1-benzyl substituted trimetoquinol affinity analogs on rat and human beta-adrenoceptors. Biochem Pharmacol 59(5):517\u2013529","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"678_CR84","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s11255-012-0275-0","volume":"44","author":"LE Meyer","year":"2012","unstructured":"Meyer LE, Brown JN (2012) Tamsulosin for voiding dysfunction in women. Int Urol Nephrol 44(6):1649\u20131656","journal-title":"Int Urol Nephrol"},{"key":"678_CR85","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/978-3-642-16499-6_15","volume":"202","author":"MC Michel","year":"2011","unstructured":"Michel MC (2011) beta-adrenergic receptor subtypes in the urinary tract. Handb Exp Pharmacol 202:307\u2013318","journal-title":"Handb Exp Pharmacol"},{"issue":"3","key":"678_CR86","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00210-013-0936-2","volume":"387","author":"MC Michel","year":"2014","unstructured":"Michel MC (2014) Do \u00df-adrenoceptor agonists induce homologous or heterologous desensitization in rat urinary bladder? Naunyn Schmiedeberg\u2019s Arch Pharmacol 387(3):215\u2013224","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"678_CR87","doi-asserted-by":"publisher","first-page":"173632","DOI":"10.1016\/j.ejphar.2020.173632","volume":"889","author":"MC Michel","year":"2020","unstructured":"Michel MC (2020) \u03b11-adrenoceptor activity of \u03b2-adrenoceptor ligands \u2013 an expected drug property with limited clinical relevance. Eur J Pharmacol 889:173632","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"678_CR88","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/nau.25082","volume":"42","author":"MC Michel","year":"2023","unstructured":"Michel MC (2023) Are \u03b23-adrenoceptor gene polymorphisms relevant for urology? Neurourol Urodyn 42(1):33\u201339","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"678_CR89","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1517\/14656566.5.1.151","volume":"5","author":"MC Michel","year":"2004","unstructured":"Michel MC, de la Rosette JJMCH (2004) Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert Opin Pharmacother 5(1):151\u2013160","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"678_CR90","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.eururo.2006.02.047","volume":"50","author":"MC Michel","year":"2006","unstructured":"Michel MC, de la Rosette JJMCH (2006) \u03b1-Blocker treatment of urolithiasis. Eur Urol 50(2):213\u2013214","journal-title":"Eur Urol"},{"issue":"5","key":"678_CR91","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1517\/14740338.2016.1160055","volume":"15","author":"MC Michel","year":"2016","unstructured":"Michel MC, Gravas S (2016) Safety and tolerability of \u00df3-adrenoceptor agonists in the treatment of overactive bladder syndrome \u2013 insight from transcriptosome and experimental studies. Expert Opin Drug Saf 15(5):647\u2013657","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"678_CR92","first-page":"270","volume":"10","author":"MC Michel","year":"2022","unstructured":"Michel MC, Staskin D (2022) Study designs for evaluation of combination treatment: focus on individual patient benefit. Biomedicine 10(2):270","journal-title":"Biomedicine"},{"issue":"Suppl. 2","key":"678_CR93","first-page":"S88","volume":"147","author":"MC Michel","year":"2006","unstructured":"Michel MC, Vrydag W (2006) \u03b11-, \u03b12- and \u00df-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 147(Suppl. 2):S88\u2013S119","journal-title":"Br J Pharmacol"},{"issue":"6","key":"678_CR94","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/sj.pcan.4500267","volume":"1","author":"MC Michel","year":"1998","unstructured":"Michel MC et al (1998) Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis 1(6):332\u2013335","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"678_CR95","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.eursup.2004.10.004","volume":"4","author":"MC Michel","year":"2005","unstructured":"Michel MC, Oelke M, Peters SLM (2005) The neuro-urological connection. Eur Urol Suppl 4(1):18\u201328","journal-title":"Eur Urol Suppl"},{"key":"678_CR96","doi-asserted-by":"crossref","unstructured":"Michel MC et al (2023) Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders. Pharmacol Rev. In press","DOI":"10.1124\/pharmrev.121.000523"},{"issue":"3","key":"678_CR97","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0022-5347(05)65926-5","volume":"166","author":"R Miyatake","year":"2001","unstructured":"Miyatake R et al (2001) Effects of isoproterenol and butylscopolamine on the friction between an artificial stone and the intraureteral wall in anaesthetized rabbits. J Urol 166(3):1083\u20131087","journal-title":"J Urol"},{"issue":"16","key":"678_CR98","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1111\/bph.13897","volume":"174","author":"W Mo","year":"2017","unstructured":"Mo W et al (2017) The \u03b23-adrenoceptor agonist mirabegron increases human atrial force through \u03b21-adrenoceptors: an indirect mechanism? Br J Pharmacol 174(16):2706\u20132715","journal-title":"Br J Pharmacol"},{"issue":"4","key":"678_CR99","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/003655900750041951","volume":"34","author":"MC Monneron","year":"2000","unstructured":"Monneron MC et al (2000) In vitro alpha-adrenoceptor autoradiography of the urethra and urinary bladder of the female pig, cat, Guinea-pig and rat. Scand J Urol Nephrol 34(4):233\u2013238","journal-title":"Scand J Urol Nephrol"},{"issue":"1","key":"678_CR100","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1464-410X.2004.04560.x","volume":"93","author":"DM Musselman","year":"2004","unstructured":"Musselman DM et al (2004) A randomized crossover study to evaluate Ro 115-1240, a selective \u03b11A\/L-adrenoceptor partial agonist in women with stress urinary incontinence. BJU Int 93(1):78\u201383","journal-title":"BJU Int"},{"issue":"1","key":"678_CR101","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1600-0773.1977.tb02049.x","volume":"40","author":"A Nergardh","year":"1977","unstructured":"Nergardh A, Boreus LO, Naglo AS (1977) Characterization of the adrenergic beta-receptor in the urinary bladder of man and cat. Acta Pharmacol Toxicol 40(1):14\u201321","journal-title":"Acta Pharmacol Toxicol"},{"issue":"10","key":"678_CR102","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/j.1742-1241.2008.01880.x","volume":"62","author":"JC Nickel","year":"2008","unstructured":"Nickel JC, Sander S, Moon TD (2008) A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 62(10):1547\u20131559","journal-title":"Int J Clin Pract"},{"issue":"4","key":"678_CR103","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1046\/j.1464-410x.1999.00218.x","volume":"84","author":"H Nishimatsu","year":"1999","unstructured":"Nishimatsu H et al (1999) Contractile responses to alpha1-adrenoceptor agonists in isolated human male and female urethra. BJU Int 84(4):515\u2013520","journal-title":"BJU Int"},{"issue":"4","key":"678_CR104","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","volume":"189","author":"V Nitti","year":"2013","unstructured":"Nitti V et al (2013a) Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 189(4):1388\u20131395","journal-title":"J Urol"},{"issue":"4","key":"678_CR105","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.juro.2013.05.062","volume":"190","author":"VW Nitti","year":"2013","unstructured":"Nitti VW et al (2013b) Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol 190(4):1320\u20131327","journal-title":"J Urol"},{"issue":"1\u20133","key":"678_CR106","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0014-2999(02)02585-2","volume":"456","author":"K Noda","year":"2002","unstructured":"Noda K et al (2002) Functional role of inhibitory and excitatory nerves in the porcine lower urinary tract. Eur J Pharmacol 456(1\u20133):81\u201390","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"678_CR107","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","volume":"64","author":"M Oelke","year":"2013","unstructured":"Oelke M et al (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64(1):118\u2013140","journal-title":"Eur Urol"},{"issue":"3","key":"678_CR108","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/j.1743-6109.2008.01138.x","volume":"6","author":"S Oger","year":"2009","unstructured":"Oger S et al (2009) Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. J Sex Med 6(3):836\u2013847","journal-title":"J Sex Med"},{"issue":"4","key":"678_CR109","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.eururo.2009.04.039","volume":"57","author":"S Oger","year":"2010","unstructured":"Oger S et al (2010) Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro. Eur Urol 57(4):699\u2013707","journal-title":"Eur Urol"},{"issue":"5","key":"678_CR110","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.eururo.2012.05.053","volume":"62","author":"EH Ohlstein","year":"2012","unstructured":"Ohlstein EH, von Keitz A, Michel MC (2012) A multicenter, double-blind, randomized, placebo controlled trial of the \u00df 3 -adrenoceptor agonist solabegron for overactive bladder. Eur Urol 62(5):834\u2013840","journal-title":"Eur Urol"},{"issue":"4","key":"678_CR111","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/sj.bjp.0703365","volume":"130","author":"J Oostendorp","year":"2000","unstructured":"Oostendorp J et al (2000) Contribution of \u00df-adrenoceptor subtypes to relaxation of colon and oesophagus and pacemaker activity of ureter in wild-type and \u00df3-adrenoceptor knockout mice. Br J Pharmacol 130(4):747\u2013758","journal-title":"Br J Pharmacol"},{"issue":"4","key":"678_CR112","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/S0022-5347(05)67200-X","volume":"164","author":"YC Park","year":"2000","unstructured":"Park YC et al (2000) Existence of a \u00df3-adrenoceptor and its functional role in the human ureter. J Urol 164(4):1364\u20131370","journal-title":"J Urol"},{"issue":"2","key":"678_CR113","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.eururo.2004.04.009","volume":"46","author":"A Reitz","year":"2004","unstructured":"Reitz A et al (2004) The effect of tamsulosin on the resting tone and the contractile behaviour of the female urethra: a functional urodynamic study in healthy women. Eur Urol 46(2):235\u2013240. discussion 240","journal-title":"Eur Urol"},{"issue":"4","key":"678_CR114","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/j.1464-410X.2007.07162.x","volume":"100","author":"D Robinson","year":"2007","unstructured":"Robinson D et al (2007) A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int 100(4):840\u2013845","journal-title":"BJU Int"},{"issue":"2","key":"678_CR115","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/sj.pcan.4500849","volume":"9","author":"CG Roehrborn","year":"2006","unstructured":"Roehrborn CG (2006) Three months\u2019 treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis 9(2):121\u2013125","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"678_CR116","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.juro.2007.09.084","volume":"179","author":"CG Roehrborn","year":"2008","unstructured":"Roehrborn CG et al (2008) The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 179(2):616\u2013621. discussion 621","journal-title":"J Urol"},{"issue":"1","key":"678_CR117","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","volume":"57","author":"CG Roehrborn","year":"2010","unstructured":"Roehrborn CG et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57(1):123\u2013131","journal-title":"Eur Urol"},{"issue":"5","key":"678_CR118","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/j.1464-410X.2007.07351.x","volume":"101","author":"A Roosen","year":"2008","unstructured":"Roosen A et al (2008) Synergistic effects in neuromuscular activation and calcium-sensitization in the bladder trigone. BJU Int 101(5):610\u2013614","journal-title":"BJU Int"},{"issue":"1","key":"678_CR119","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ceca.2008.05.002","volume":"45","author":"A Roosen","year":"2009","unstructured":"Roosen A et al (2009a) Adreno-muscarinic synergy in the bladder trigone: calcium-dependent and -independent mechanisms. Cell Calcium 45(1):11\u201317","journal-title":"Cell Calcium"},{"issue":"8","key":"678_CR120","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/nau.20742","volume":"28","author":"A Roosen","year":"2009","unstructured":"Roosen A et al (2009b) Clinical and experimental aspects of adreno-muscarinic synergy in the bladder base and prostate. Neurourol Urodyn 28(8):938\u2013943","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"678_CR121","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0002-9440(10)61159-5","volume":"160","author":"MR Saban","year":"2002","unstructured":"Saban MR et al (2002) Gene expression profiling of mouse bladder inflammatory responses to LPS, substance P, and antigen stimulation. Am J Pathol 160(6):2095\u20132110","journal-title":"Am J Pathol"},{"issue":"3","key":"678_CR122","first-page":"388","volume":"74","author":"V Sakalis","year":"2021","unstructured":"Sakalis V et al (2021) The effect of pharmacotherapy on prostate volume, prostate perfusion and prostate-specific antigen (prostate morphometric parameters) in patients with lower urinary tract symptoms and benign prostatic obstruction. A systematic review and meta-analysis. Cent European J Urol 74(3):388\u2013421","journal-title":"Cent European J Urol"},{"key":"678_CR123","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fphar.2010.00128","volume":"1","author":"T Schneider","year":"2010","unstructured":"Schneider T, Michel MC (2010) Can [125I]-iodocyanopindolol label \u00df3-adrenoceptors in rat urinary bladder? Front Pharmacol 1:128","journal-title":"Front Pharmacol"},{"issue":"3","key":"678_CR124","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1442-2042.2007.01956.x","volume":"15","author":"DA Schwinn","year":"2008","unstructured":"Schwinn DA, Roehrborn CG (2008) Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 15(3):193\u2013199","journal-title":"Int J Urol"},{"key":"678_CR125","first-page":"1035","volume":"275","author":"MA Scofield","year":"1995","unstructured":"Scofield MA et al (1995) Quantification of steady state expression of mRNA for alpha-1 adrenergic receptor subtypes using reverse transcription and a competitive polymerase chain reaction. J Pharmacol Exp Ther 275:1035\u20131042","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"678_CR126","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00210-018-1510-8","volume":"391","author":"D Sellers","year":"2018","unstructured":"Sellers D, Chess-Williams R, Michel MC (2018) Modulation of lower urinary tract smooth muscle contraction and relaxation by the urothelium. Naunyn Schmiedeberg\u2019s Arch Pharmacol 391(7):675\u2013694","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"3","key":"678_CR127","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0022-5347(17)44107-3","volume":"137","author":"E Shapiro","year":"1987","unstructured":"Shapiro E, Tsitlik JE, Lepor H (1987) Alpha 2 adrenergic receptors in canine prostate: biochemical and functional correlations. J Urol 137(3):565\u2013570","journal-title":"J Urol"},{"issue":"4","key":"678_CR128","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.lfs.2004.09.008","volume":"76","author":"S Sigala","year":"2004","unstructured":"Sigala S et al (2004) Alpha1 adrenoceptor subtypes in human urinary bladder: sex and regional comparison. Life Sci 76(4):417\u2013427","journal-title":"Life Sci"},{"issue":"4","key":"678_CR129","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/j.1464-410X.1988.tb13963.x","volume":"61","author":"MJ Speakman","year":"1988","unstructured":"Speakman MJ, Walmsley D, Brading AF (1988) An in vitro pharmacological study of the human trigone\u2013a site of non-adrenergic, non-cholinergic neurotransmission. Br J Urol 61(4):304\u2013309","journal-title":"Br J Urol"},{"issue":"6","key":"678_CR130","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00210-020-02044-4","volume":"394","author":"A Spek","year":"2021","unstructured":"Spek A et al (2021) Purinergic smooth muscle contractions in the human prostate: estimation of relevance and characterization of different agonists. Naunyn Schmiedeberg\u2019s Arch Pharmacol 394(6):1113\u20131131","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"2","key":"678_CR131","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/JU.0000000000000807","volume":"204","author":"D Staskin","year":"2020","unstructured":"Staskin D et al (2020) International phase III, randomized, double-blind, placebo- and active-controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol 204(2):316\u2013324","journal-title":"J Urol"},{"issue":"10","key":"678_CR132","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/j.1464-410X.2010.09228.x","volume":"106","author":"T Streng","year":"2010","unstructured":"Streng T, Santti R, Andersson KE (2010) Voiding effects mediated by alpha2-adrenoceptors in the anaesthetized male rat. BJU Int 106(10):1546\u20131549","journal-title":"BJU Int"},{"issue":"2\u20133","key":"678_CR133","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ejphar.2010.10.052","volume":"650","author":"F Strittmatter","year":"2011","unstructured":"Strittmatter F et al (2011) Thromboxane A2 induces contraction of human prostate smooth muscle by Rho kinase- and calmodulin-dependent mechanisms. Eur J Pharmacol 650(2\u20133):650\u2013655","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"678_CR134","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/pros.23108","volume":"76","author":"T Suzuki","year":"2016","unstructured":"Suzuki T et al (2016) The expression of beta3-adrenoceptors and their function in the human prostate. Prostate 76(2):163\u2013171","journal-title":"Prostate"},{"issue":"4","key":"678_CR135","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/nau.20365","volume":"26","author":"R Takahashi","year":"2007","unstructured":"Takahashi R et al (2007) RhoA\/Rho kinase-mediated Ca2+ sensitization in the contraction of human prostate. Neurourol Urodyn 26(4):547\u2013551","journal-title":"Neurourol Urodyn"},{"issue":"2 Pt 1","key":"678_CR136","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/01.ju.0000074622.50255.a8","volume":"170","author":"H Takeda","year":"2003","unstructured":"Takeda H et al (2003) Functional characterization of beta-adrenoceptor subtypes in the canine and rat lower urinary tract. J Urol 170(2 Pt 1):654\u2013658","journal-title":"J Urol"},{"key":"678_CR137","doi-asserted-by":"publisher","first-page":"119771","DOI":"10.1016\/j.lfs.2021.119771","volume":"281","author":"A Tamalunas","year":"2021","unstructured":"Tamalunas A et al (2021a) Lenalidomide and pomalidomide inhibit growth of prostate stromal cells and human prostate smooth muscle contraction. Life Sci 281:119771","journal-title":"Life Sci"},{"issue":"7","key":"678_CR138","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/pros.24114","volume":"81","author":"A Tamalunas","year":"2021","unstructured":"Tamalunas A et al (2021b) Inhibition of human prostate stromal cell growth and smooth muscle contraction by thalidomide: a novel remedy in LUTS? Prostate 81(7):377\u2013389","journal-title":"Prostate"},{"issue":"5","key":"678_CR139","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ejps.2012.03.001","volume":"46","author":"S Tasler","year":"2012","unstructured":"Tasler S et al (2012) An aryloxypropanolamine hbeta3-adrenoceptor agonist as bladder smooth muscle relaxant. Eur J Pharm Sci 46(5):381\u2013387","journal-title":"Eur J Pharm Sci"},{"issue":"7","key":"678_CR140","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/nau.20312","volume":"25","author":"S Tatemichi","year":"2006","unstructured":"Tatemichi S et al (2006) Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia. Neurourol Urodyn 25(7):792\u2013799. discussion 800\u2013801","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"678_CR141","doi-asserted-by":"publisher","first-page":"486 e9\u201316","DOI":"10.1016\/j.urology.2012.01.039","volume":"80","author":"S Tatemichi","year":"2012","unstructured":"Tatemichi S et al (2012) Comparison of the effects of four alpha1-adrenoceptor antagonists on ejaculatory function in rats. Urology 80(2):486 e9\u201316","journal-title":"Urology"},{"issue":"4","key":"678_CR142","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.bcp.2007.06.004","volume":"74","author":"CE Teixeira","year":"2007","unstructured":"Teixeira CE et al (2007) Comparative pharmacological analysis of Rho-kinase inhibitors and identification of molecular components of Ca2+ sensitization in the rat lower urinary tract. Biochem Pharmacol 74(4):647\u2013658","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"678_CR143","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/14656566.2016.1186645","volume":"17","author":"G Thiagamoorthy","year":"2016","unstructured":"Thiagamoorthy G, Cardozo L, Robinson D (2016) Current and future pharmacotherapy for treating overactive bladder. Expert Opin Pharmacother 17(10):1317\u20131325","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"678_CR144","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1254\/jphs.92.411","volume":"92","author":"Y Tomiyama","year":"2003","unstructured":"Tomiyama Y et al (2003a) Pharmacological profile of KUL-7211, a selective \u00df-adrenoceptor agonist, in isolated ureteral smooth muscle. J Pharmacol Sci 92(4):411\u2013419","journal-title":"J Pharmacol Sci"},{"issue":"3","key":"678_CR145","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000070171","volume":"68","author":"Y Tomiyama","year":"2003","unstructured":"Tomiyama Y et al (2003b) Comparison between CL-316243- and CGP-12177A-induced relaxations in isolated canine ureter. Pharmacology 68(3):140\u2013146","journal-title":"Pharmacology"},{"issue":"6","key":"678_CR146","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2165\/00003495-200969060-00003","volume":"69","author":"V Tzortzis","year":"2009","unstructured":"Tzortzis V et al (2009) Medical expulsive therapy for distal ureteral stones. Drugs 69(6):677\u2013692","journal-title":"Drugs"},{"issue":"3\u20134","key":"678_CR147","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0014-2999(84)90484-9","volume":"103","author":"S Ueda","year":"1984","unstructured":"Ueda S, Satake N, Shibata S (1984) Alpha 1- and alpha 2-adrenoceptors in the smooth muscle of isolated rabbit urinary bladder and urethra. Eur J Pharmacol 103(3\u20134):249\u2013254","journal-title":"Eur J Pharmacol"},{"issue":"6220","key":"678_CR148","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen M et al (2015) Tissue-based map of the human proteome. Science 347(6220):1260419","journal-title":"Science"},{"issue":"1","key":"678_CR149","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0014-2999(97)89674-4","volume":"327","author":"PH Van der Graaf","year":"1997","unstructured":"Van der Graaf PH et al (1997) Analysis of alpha1-adrenoceptors in rabbit lower urinary tract and mesenteric artery. Eur J Pharmacol 327(1):25\u201332","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"678_CR150","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2165\/00003495-200666030-00002","volume":"66","author":"MM van Dijk","year":"2006","unstructured":"van Dijk MM, de la Rosette JJ, Michel MC (2006) Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs 66(3):287\u2013301","journal-title":"Drugs"},{"issue":"1","key":"678_CR151","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/bph.12123","volume":"169","author":"L Villa","year":"2013","unstructured":"Villa L et al (2013) Effects of silodosin on the partially obstructed rat ureter in vivo and on human and rat isolated ureters. Br J Pharmacol 169(1):230\u2013238","journal-title":"Br J Pharmacol"},{"issue":"3","key":"678_CR152","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/S0022-5347(01)65136-X","volume":"157","author":"PD Walden","year":"1997","unstructured":"Walden PD et al (1997) Localization of mRNA and receptor binding sites for the alpha 1a-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate. J Urol 157(3):1032\u20131038","journal-title":"J Urol"},{"issue":"7","key":"678_CR153","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1002\/nau.23578","volume":"37","author":"S Walther","year":"2018","unstructured":"Walther S et al (2018) Adreno-muscarinic synergy in the male human urinary outflow tract. Neurourol Urodyn 37(7):2128\u20132134","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"678_CR154","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/01.ju.0000133557.39515.b6","volume":"172","author":"I Wanajo","year":"2004","unstructured":"Wanajo I et al (2004) Pharmacological characterization of \u00df-adrenoceptor subtypes mediating relaxation in porcine isolated ureteral smooth muscle. J Urol 172(3):1155\u20131159","journal-title":"J Urol"},{"key":"678_CR155","doi-asserted-by":"publisher","first-page":"172985","DOI":"10.1016\/j.ejphar.2020.172985","volume":"873","author":"X Wang","year":"2020","unstructured":"Wang X et al (2020) Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by alpha1-blockers. Eur J Pharmacol 873:172985","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"678_CR156","first-page":"123","volume":"16","author":"RM Weiss","year":"1978","unstructured":"Weiss RM, Basset AL, Hoffman BF (1978) Adrenergic innervation of the ureter. Investig Urol 16(2):123\u2013127","journal-title":"Investig Urol"},{"issue":"1\u20133","key":"678_CR157","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ejphar.2013.09.012","volume":"721","author":"CW White","year":"2013","unstructured":"White CW, Short JL, Ventura S (2013) Rho kinase activation mediates adrenergic and cholinergic smooth muscle contractile responses in the mouse prostate gland. Eur J Pharmacol 721(1\u20133):313\u2013321","journal-title":"Eur J Pharmacol"},{"issue":"14","key":"678_CR158","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1111\/bph.14599","volume":"176","author":"CW White","year":"2019","unstructured":"White CW et al (2019) What makes the \u03b11A-adrenoceptor gene product assume a \u03b11L-adrenoceptor phenotype? Br J Pharmacol 176(14):2358\u20132365","journal-title":"Br J Pharmacol"},{"issue":"1","key":"678_CR159","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1124\/jpet.108.142562","volume":"328","author":"M Wuest","year":"2009","unstructured":"Wuest M et al (2009) Catecholamines relax detrusor through \u00df2-adrenoceptors in mouse and \u00df3-adrenoceptors in man. J Pharmacol Exp Ther 328(1):213\u2013222","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"678_CR160","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00345-011-0655-6","volume":"29","author":"M Wuest","year":"2011","unstructured":"Wuest M et al (2011) The muscarinic receptor antagonist propiverine exhibits alpha(1)-adrenoceptor antagonism in human prostate and porcine trigonum. World J Urol 29(2):149\u2013155","journal-title":"World J Urol"},{"issue":"4","key":"678_CR161","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/nau.10130","volume":"22","author":"T Yamanishi","year":"2003","unstructured":"Yamanishi T et al (2003) Role of beta-adrenoceptor subtypes in mediating relaxation of the pig bladder trigonal muscle in vitro. Neurourol Urodyn 22(4):338\u2013342","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"678_CR162","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1620\/tjem.192.181","volume":"192","author":"T Yanagisawa","year":"2000","unstructured":"Yanagisawa T et al (2000) Selectivity and potency of agonists for the three subtypes of cloned human beta-adrenoceptors expressed in Chinese hamster ovary cells. Tohoku J Exp Med 192(3):181\u2013193","journal-title":"Tohoku J Exp Med"},{"issue":"5","key":"678_CR163","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2220\/biomedres.29.239","volume":"29","author":"H Yanase","year":"2008","unstructured":"Yanase H et al (2008) The involvement of urothelial alpha1A adrenergic receptor in controlling the micturition reflex. Biomed Res 29(5):239\u2013244","journal-title":"Biomed Res"},{"issue":"5","key":"678_CR164","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.eururo.2017.12.022","volume":"73","author":"M Yoshida","year":"2018","unstructured":"Yoshida M et al (2018) Vibegron, a novel potent and selective b3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol 73(5):783\u2013790","journal-title":"Eur Urol"},{"issue":"4","key":"678_CR165","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/ijir.2017.12","volume":"29","author":"HL Zhang","year":"2017","unstructured":"Zhang HL et al (2017) Tamsulosin for treatment of lower urinary tract symptoms in women: a systematic review and meta-analysis. Int J Impot Res 29(4):148\u2013156","journal-title":"Int J Impot Res"}],"container-title":["Handbook of Experimental Pharmacology","Adrenoceptors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2023_678","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T15:03:24Z","timestamp":1725375804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2023_678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9783031667756","9783031667763"],"references-count":165,"URL":"https:\/\/doi.org\/10.1007\/164_2023_678","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"17 July 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"Work in the labs of the authors related to LUTD is funded by Deutsche Forschungsgemeinschaft HE 5825\/9-1 to MH and 294\/10-1 to MCM.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MH reports no conflicts of interest. MCM has received consultancy, lecturer honorary, and\/or travel reimbursement in the field of LUTD from Apogepha, Astellas, Dr. Willmar Schwabe, Sanofi-Aventis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}